OakChart

Telix Pharmaceuticals Ltd ADR

TLXHealthcare·Biotechnology·Australia·Mid·NASD·Nov 11 • 1:27 PM ET

9.74+0.30 (3.12%)
2026-11-11 19:29 CET
Market cap
3,216.12 USD m
Revenue, TTM
893.10 USD m
Net income, TTM
33.62 USD m
Free cash flow, TTM
-57.73 USD m
EPS diluted, TTM
0.09
P/E
104.22
Compare

Price

TLX against its 20, 50 and 200-day averages
2050200beat
9.0010.0011.0012.0013.00539K1.1MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TLXclose 9.7520-day 9.6850-day 10.76200-day 9.989.7552w high

25.7% under the 52-week high of 13.11 on 15 Sep 2026. 52-week low 6.28 on 17 Feb 2026. Last 15 sessions, 11.8% high to low

Profile

TLX
52-week range, 51% of the way up
6.2813.11

Telix Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development and commercialization of several clinical-stage oncology assets. The firm operates through the following segments: Therapeutics (Tx), Precision Medicine (Px), and Telix Manufacturing Solutions (TMS). The Tx segment focuses on development of targeted radionuclide therapies for urologic and neurologic oncology, and other solid tumors. The Px segment includes provision of diagnostic imaging solutions to market and expanding into new geographies and indications. The TMS segment comprises of costs to operate the firm's facilities and assets. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East and Africa. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in North Melbourne, Australia.

Employees1184
IPONov 14, 2024
Beta-0.08
ATR, 14d0.39
Rel volume0.74
Inst own0.97%

Snapshot

6 groups

Valuation

Index-
Market Cap3.32B
Enterprise Value3.64B
Income33.62M
Sales893.10M
Book/sh1.44
Cash/sh0.74
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees1184
IPONov 14, 2024

Ratios

P/E104.22
Forward P/E190.97
PEG-
P/S3.71
P/B6.79
P/C13.17
P/FCF-
EV/EBITDA119.57
EV/Sales4.08
Quick Ratio1.85
Current Ratio2.01
Debt/Eq1.19
LT Debt/Eq1.16
Option/ShortNo / Yes

Earnings

EPS (ttm)0.09
EPS next Y0.05
EPS next Q0.06
EPS this Y507.58%
EPS next Y-40.66%
EPS next 5Y-
EPS past 3/5Y55.05% 29.38%
Sales past 3/5Y93.54% 195.21%
EPS Y/Y TTM198.49%
Sales Y/Y TTM33.78%
EPS Q/Q-
Sales Q/Q-
EarningsAug 19 AMC
EPS/Sales Surpr.140.27% -0.55%

Ownership

Insider Own-
Insider Trans-
Inst Own0.97%
Inst Trans0.33%
ROA2.63%
ROE7.39%
ROIC3.20%
Gross Margin52.13%
Oper. Margin-0.81%
Profit Margin3.76%
SMA200.64%
SMA50-9.46%
SMA200-2.33%
Trades-

Technical

Shs Outstand334.13M
Shs Float-
Short Float-
Short Ratio0.80
Short Interest0.27M
52W High13.11 -25.67%
52W Low6.28 55.18%
Volatility3.50% 2.25%
ATR (14)0.39
RSI (14)47.28
Beta-0.08
Rel Volume0.74
Avg Volume339.60K
Volume158,298

Performance

Perf Week0.78%
Perf Month-10.76%
Perf Quarter-20.97%
Perf Half Y-7.37%
Perf YTD30.11%
Perf Year-4.74%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.29
Target Price17.88
Prev Close9.45
Price9.74
Change %3.12%

Analyst ratings

latest 6 of 6
DateActionAnalystRating changeTargetImplied
Jul 17, 2026DowngradeRRBC Capital MktsOutperform → Sector Perform
Sep 18, 2025InitiatedCCitigroupBuy$22+125.8%
Aug 28, 2025DowngradeJJP MorganOverweight → Neutral
Jul 03, 2025InitiatedHH.C. WainwrightBuy$23+136.0%
Jun 05, 2025InitiatedWWedbushOutperform$22+125.8%
Nov 15, 2024InitiatedUUBSBuy$21+115.5%

Peers

Mkt cap
TickerCompanyMkt cap
LNTHLantheus Holdings Inc6.64B
AKTSAktis Oncology Inc977.23M
DRTSAlpha Tau Medical Ltd1.33B
IMNMImmunome Inc2.25B
NVSNovartis AG ADR292.39B
RADXRadiopharm Theranostics Ltd ADR13.35M
CATXPerspective Therapeutics Inc99.46M
GEHCGE HealthCare Technologies Inc37.40B
BWXTBWX Technologies Inc11.64B
ASPIASP Isotopes Inc307.38M

Insider trading

4 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Smith Darren CharltonGroup Chief Financial OfficerSep 07 '26Buy9.662,07119,99813,992Sep 14 07:20 PM
Behrenbruch ChristianMD & Group CEOApr 28 '26Buy14.4834,500499,56020,709,500May 06 09:32 PM
Behrenbruch ChristianMD & Group CEOApr 29 '26Buy14.8733,435497,17820,742,935May 06 09:32 PM
Smith Darren CharltonGroup Chief Financial OfficerMar 29 '26Option Exercise0.001,111011,921Apr 01 07:14 PM

Held by

AUM
TickerCompanyAUM
APIEActivePassive International Equity ETFAUM: 1.13B

News

latest 14 of 100
  • Telix to Participate in UBS Global Biopharma Conference (PR Newswire)
  • Telix Joins Thera4Care with TLX400-Tx to Accelerate Translation of Next Generation FAP-Targeting Theranostics (PR Newswire)
  • Telix Reports Third Quarter 2026 Financial Performance (GlobeNewswire) -10.13%
  • Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S. (GlobeNewswire)
  • Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM (PR Newswire)
  • Profound Medical and Telix Pharmaceuticals Partner to Advance Prostate Cancer Imaging and Treatment Education (InvestorsHub)
  • First Patients Dosed with Telix's FDA-Approved Brain Cancer Imaging Drug Pixclara (floretyrosine F 18) (GlobeNewswire)
  • Telix to acquire ITM in deal worth up to $2.35bn (Pharmaceutical Technology) -10.17%
  • Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse (GlobeNewswire)
  • FDA Approves Telix's Brain Cancer Imaging Drug Pixclara (GlobeNewswire)
  • Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • TLX Stock Clocks 5% Gain This Week Ahead Of FDA Decision On Brain Cancer Imaging Agent (Stocktwits)
  • Telix Pharmaceuticals Shares Rise 5.3% as Analyst Highlights BiPASS Trial and FDA Pathway (InvestorsHub) +5.53%
  • Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026S12026-08-190.1070.0450.110477479.638
2025S22026-02-19-0.0190.033-0.014413.37418.496
2025S12025-08-20-0.0070.133-0.007390.36390.497
2024S22025-02-200.1120.0920.038267.24135.063
2024S12024-08-220.0590.0890.058246.48237.815
2026S2---0.044--493.847
2027S1--0.015--694.235
2027S2--0.023--749.375
2028S1--0.204--865.814
2028S2--0.284--987.983
2029S1--0.126---1
2029S2--0.149---1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY0.0830.0600.011329.7335.87
2024FY0.0920.1500.095499.29485.11
2025FY-0.0210.005-0.021803.8804
2026FY-0.086--977.74
2027FY-0.051--1,279
2028FY-0.249--1,500
2029FY-1.163--1,794
2030FY-0.790--1,658

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026S2S2026-11-03710493.84488.5503.1
2026S2S2026-10-21711493.82488.5503.1
2026S2S2026-10-10711494.64488.5503.1
2026S2S2026-10-09712494.64488.5503.1
2026S2S2026-10-04712494.63488.5503.1
2026S2S2026-09-18722494.63488.5503.1
2026S2S2026-09-16722494.64488.5503.1
2026S2S2026-09-14722494.53488.5502.3
2026S2S2026-09-11622494.02488.5502.3
2026S2S2026-09-03622494.02488.5502.3
2026S2S2026-09-02522495.12490502.3
2026S2S2026-09-01623494.93490502.3
2026S2S2026-08-20614493.27480.3502.3
2026S2S2026-07-27613496.2480.9510

Estimate history

EPS, annual-0.038-0.051-0.083-0.12-0.214-0.2320.0110.095-0.021
Period201720182019202020212022202320242025
EPS, quarterly
Period
Sales, annual00.1462.4223.5895.701110.984333.574516.603804.637
Period201720182019202020212022202320242025
Sales, quarterly
Period
Shares, annual197.438218.366253.28280.405285.073316.343323.727334.725338.778
Period201720182019202020212022202320242025
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue893.10804.64516.60333.57110.985.703.592.420.15
Cost of Goods Sold Incl. D&A427.48377.28179.98124.6390.6528.0415.2110.67-
Gross Profit465.62427.36336.62208.9420.34-22.34-11.62-8.25-
Selling, General and Administrative Excl. Other472.85409.58282.54174.7571.0738.6422.2919.7220.78
Research and Development214.06171.43128.3885.3240.1125.6215.8914.7113.96
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-7.2317.7854.0934.19-50.73-60.98-33.91-27.98-20.64
Interest Expense12.6736.7614.160.660.280.140.811.670.02
Unusual Expense-19.09-8.8722.1523.1712.2911.155.02--
Net Income Before Taxes28.92-5.2736.972.05-68.37-74.34-41.48-29.75-19.31
Income Taxes-4.701.864.05-1.413.78-13.91-10.58-10.39-8.98
Consolidated Net Income33.62-7.1332.933.46-72.15-60.43-30.90-19.37-10.33
Net Income From Continuing Operations33.62-7.1332.933.46-72.15-60.43-30.90-19.37-10.33
Net Income33.62-7.1332.933.46-72.15-60.43-30.90-19.37-10.33
EPS (Recurring)0.06-0.040.140.06-0.20-0.19-0.11-0.08-0.05
EPS (Basic, Before Extraordinaries)0.10-0.020.100.01-0.23-0.21-0.12-0.08-0.05
EPS (Diluted)0.09-0.020.100.01-0.23-0.21-0.12-0.08-0.05
EBITDA30.4839.5959.5038.79-47.00-57.10-30.55-25.03-20.64
Non-Operating Income (Expense)29.734.8319.19-8.31-5.07-2.06-1.74-0.101.36
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense13.8213.429.084.083.940.691.130.620.84
Price To Earnings Ratio95.3695.36155.71162.79-----
Price To Sales Ratio4.613.1510.29------
Gross Margin52.1353.1165.1662.6418.32-391.85-323.75-340.75-
Operating Margin-0.812.2110.4710.25-45.71-1,069.60-944.81-1,155.12-14,167.65
Net Margin3.76-0.896.371.04-65.01-1,059.90-861.06-799.63-7,087.07
Shares Outstanding339.79338.78334.73323.73316.34285.07280.41253.28218.37
Market Capitalization3,216.123,216.125,154.755,389.02-----

Income statement, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S22023S12022S2
Total Revenue478.95414.15390.48277.13239.54183.86149.1991.15
Cost of Goods Sold Incl. D&A231.89195.59181.4197.9181.9837.6887.8461.07
Gross Profit247.06218.56209.08179.22157.56146.1861.3530.07
Selling, General and Administrative Excl. Other260.85212.00197.58159.95128.04133.0840.1136.58
Research and Development124.2489.8281.6173.0155.4164.2220.5722.12
Other Operating Expense0.000.000.390.000.060.000.000.00
Operating Income-13.796.5611.1019.2729.4613.1021.24-6.50
Interest Expense4.877.806.430.400.440.360.300.18
Unusual Expense-5.59-13.502.019.752.02-1.1027.726.19
Net Income Before Taxes29.35-0.43-4.8414.1322.8310.04-8.31-18.70
Income Taxes-9.114.41-2.540.733.31-2.701.363.53
Consolidated Net Income38.46-4.84-2.2913.4019.5212.75-9.67-22.23
Net Income From Continuing Operations38.46-4.84-2.2913.4019.5212.75-9.67-22.23
Net Income38.46-4.84-2.2913.4019.5212.75-9.67-22.23
EPS (Recurring)0.10-0.04-0.000.060.060.040.03-0.06
EPS (Basic, Before Extraordinaries)0.11-0.01-0.010.040.060.04-0.03-0.07
EPS (Diluted)0.11-0.01-0.010.040.060.04-0.03-0.07
EBITDA11.9818.5020.6922.1231.8915.4823.46-4.72
Non-Operating Income (Expense)42.42-12.69-7.505.00-4.17-3.81-1.53-5.84
Stock Option Compensation Expense8.525.308.114.504.583.410.621.29
Price To Earnings Ratio95.36225.60161.35155.71162.79---
Price To Sales Ratio4.613.158.1210.58----
Gross Margin51.5852.7753.5464.6765.7879.5041.1233.00
Operating Margin-2.881.582.846.9512.307.1314.24-7.13
Net Margin8.03-1.17-0.594.838.156.93-6.48-24.39
Shares Outstanding339.79338.78338.40334.73334.23323.73318.56316.34
Market Capitalization3,216.122,537.335,437.815,154.755,389.02---

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments141.87439.8184.0978.8916.0260.1531.3518.1438.14
Short Term Receivables138.3798.4454.2731.1415.1610.959.146.320.38
Inventories37.0823.6211.815.752.510.490.380.450.00
Other Current Assets12.966.868.481.700.880.660.370.330.23
Total Current Assets330.28568.73158.65117.4834.5772.2541.2525.2438.75
Net Property, Plant & Equipment115.6133.6320.8112.774.603.721.330.160.00
Total Investments and Advances37.0934.738.370.000.000.000.000.000.00
Long-Term Note Receivable--0.40---0.000.80-
Intangible Assets592.82257.6574.8340.0040.5245.6729.4927.771.18
Deferred Tax Assets77.4734.9816.636.25-5.11---
Other Assets28.8215.220.400.220.150.140.060.030.03
Total Assets1,182.11944.94279.68176.7279.84126.8972.1354.0039.96
Short Term Debt Incl. Current Port. of LT Debt18.6613.301.060.430.460.590.340.800.27
Accounts Payable71.6642.5322.4111.408.644.484.902.290.22
Income Tax Payable30.7430.0813.084.96-----
Other Current Liabilities110.56118.9776.0841.2218.5210.332.232.720.66
Total Current Liabilities231.62204.88112.6358.0227.6115.407.475.801.15
Long Term Debt448.45346.7010.846.651.391.111.150.420.00
Provision for Risks Charges9.627.554.260.150.100.000.000.000.00
Deferred Tax Liabilities62.8311.852.673.55-5.112.233.080.26
Other Liabilities14.2120.8646.2452.6448.0943.5411.567.460.00
Total Liabilities766.73591.85176.65121.0177.1965.1622.4116.761.41
Non-Equity Reserves0.001.281.421.461.080.760.460.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity415.38351.81101.6154.261.5760.9749.2637.2438.55
Total Shareholders Equity415.38351.81101.6154.261.5760.9749.2637.2438.55
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity415.38351.81101.6154.261.5760.9749.2637.2438.55
Total Liabilities & Stockholders Equity1,182.11944.94279.68176.7279.84126.8972.1354.0039.96
Book Value Per Share1.231.050.310.170.010.220.190.170.20
Tangible Book Value Per Share-0.520.280.080.05-0.140.050.080.040.19
Full-Time Employees1,1845543472341587260509
Price to Book Ratio6.5819.0819.95------
Return on Assets-0.675.401.52-56.24-58.46-31.05-30.71-21.98-
Return on Equity-1.8614.524.44-258.49-193.24-56.06-44.77-27.25-
Return on Invested Capital-0.834.713.08-118.46-2,044.64-49.77-38.41-27.42-12.68
Quick Ratio1.272.661.301.931.164.665.474.2733.74
Current Ratio1.432.781.412.021.254.695.524.3533.74

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income--5.2736.972.05-68.37-60.43-30.90-19.37-10.33
Depreciation-21.435.414.603.733.883.362.940.01
Other Funds (Non Cash)-11.7928.3931.4520.9913.996.990.46-1.99
Funds from Operations33.3327.9570.7738.09-43.65-42.56-20.55-15.96-12.31
Extraordinary Item-0.000.000.000.000.000.000.000.00
Changes in Working Capital--45.26-42.39-22.24-0.70-1.9721.90-0.25-3.19
Cash from Operating Activities-11.96-17.3128.3815.85-44.35-44.531.35-16.22-15.49
Capital Expenditures-47.10-56.06-31.98-7.16-9.61-1.01-0.22-0.330.00
Net Assets From Acquisitions3.69-220.89-20.380.00-0.670.00-0.220.00-2.01
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-1.07-0.89-34.29-8.730.000.000.000.000.00
Purchase of Investments-1.07-0.89-34.29-8.730.000.000.000.00-
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses-16.83-8.38-2.51-1.02-1.50-1.04-0.310.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-61.31-286.22-89.16-16.92-11.78-2.05-0.75-0.33-2.01
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock2.511.810.664.42120.082.8424.1130.500.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock2.511.810.664.42120.082.8424.1130.500.00
Proceedsfrom Stock Options2.511.810.664.42120.082.8424.1130.500.00
Issuance or Reduction of Debt, Net121.57-0.29431.923.822.08-0.26-0.28-0.66-0.65
Change in Long Term Debt0.16-0.29431.923.822.080.000.000.000.00
Issuance of Long Term Debt0.530.53432.663.822.090.000.000.000.00
Reduction of Long Term Debt-0.37-0.82-0.740.00-0.010.000.000.000.00
Net Financing Active Other Cash Flow0.000.00-9.820.000.000.000.000.000.00
Other Financing Activities Uses0.000.00-9.820.000.000.000.000.000.00
Cash from Financing Activities118.02-3.72421.436.76121.292.1423.4929.69-0.65
Exchange Rate Effect-0.078.8126.60-1.110.212.48-1.13-0.070.99
Net Change in Cash44.68-298.45387.264.5965.37-41.9622.9613.08-17.17
Free Cash Flow-57.73-55.279.409.43-49.22-45.531.18-16.50-15.49
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow--565.64------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Cash & Short Term Investments251.91141.87207.16439.8179.3784.09
Short Term Receivables170.39138.37129.5298.4464.9649.05
Inventories39.0337.0835.2323.6220.5711.81
Other Current Assets26.6912.9626.106.865.588.48
Total Current Assets488.02330.28398.01568.73170.48153.43
Net Property, Plant & Equipment129.63115.6174.1833.6325.5520.81
Total Investments and Advances40.4137.0936.7134.736.998.37
Intangible Assets584.61592.82584.17257.65266.7974.83
Deferred Tax Assets85.3077.4775.7734.9824.5116.63
Other Assets33.8828.8221.1115.223.870.00
Total Assets1,361.851,182.111,189.95944.94498.19274.46
Short Term Debt Incl. Current Port. of LT Debt15.4218.6621.0613.302.521.06
Accounts Payable168.9771.6651.6942.5314.8922.41
Income Tax Payable33.8530.7451.7430.0822.687.85
Other Current Liabilities24.10110.56174.09118.97132.4576.08
Total Current Liabilities242.34231.62298.58204.88172.55107.41
Long Term Debt564.44448.45397.19346.7012.2610.84
Deferred Tax Liabilities43.3062.8339.1911.856.422.67
Other Liabilities15.5314.2123.3720.8631.6150.28
Total Liabilities874.18766.73768.01591.85228.39171.42
Non-Equity Reserves0.000.000.001.280.001.42
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity487.67415.38421.94351.81269.79101.61
Total Shareholders Equity487.67415.38421.94351.81269.79101.61
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity487.67415.38421.94351.81269.79101.61
Total Liabilities & Stockholders Equity1,361.851,182.111,189.95944.94498.19274.46
Book Value Per Share1.441.231.251.050.810.31
Tangible Book Value Per Share-0.29-0.52-0.480.280.010.08
Price to Book Ratio6.586.0115.2919.0819.95-
Return on Assets2.63-0.671.325.409.161.36
Return on Equity7.39-1.863.2114.5220.143.94
Return on Invested Capital3.66-0.56-0.281.926.9211.34
Quick Ratio1.851.271.222.660.871.32
Current Ratio2.011.431.332.780.991.43

Cash flow, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Funds from Operations23.1110.2217.7545.2125.7228.50
Extraordinary Item-0.000.00---
Cash from Operating Activities23.11-35.0817.752.7225.726.63
Capital Expenditures-19.36-27.73-28.36-18.49-13.57-5.01
Net Assets From Acquisitions0.003.69-224.73-5.16-15.260.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00-0.08
Purchase or Sale of Investments-1.00-0.07-0.83-33.06-1.31-8.59
Purchase of Investments-1.00-0.07-0.83-33.06-1.31-8.59
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses-13.46-3.36-5.02-2.48-0.03-1.01
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-33.83-27.48-258.94-59.18-30.17-14.69
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.371.130.680.240.422.36
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.371.130.680.240.422.36
Proceedsfrom Stock Options1.371.130.680.240.422.36
Issuance or Reduction of Debt, Net121.410.16-0.45431.361.492.08
Change in Long Term Debt0.000.16-0.45431.361.492.08
Issuance of Long Term Debt0.000.530.00431.811.782.08
Reduction of Long Term Debt0.00-0.37-0.45-0.45-0.290.00
Net Financing Active Other Cash Flow0.000.000.00-9.840.000.00
Other Financing Activities Uses0.000.000.00-9.840.000.00
Cash from Financing Activities118.82-0.80-2.92420.921.423.47
Exchange Rate Effect2.31-2.3711.1926.520.14-1.31
Net Change in Cash110.41-65.73-232.92390.99-2.90-5.90
Free Cash Flow4.08-61.816.51-10.4719.892.35
Price to Free Cash Flow---580.17--

Revenue breakdown

China2024: 382.00K 2025: 9.83M
Foreign countries2024: 13.41M 2025: 9.06M
United States2024: 502.76M 2025: 784.91M
Manufacturing Solutions2024: 1.82M 2025: 172.59M
Precision Medicine2024: 508.51M 2025: 621.93M
Therapeutics2024: 6.23M 2025: 9.27M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-30-0.3M-318.21K
2026-10-15-0.4M-271.66K
2026-09-30-0.4M-246.40K
2026-09-15-0.4M-188.40K
2026-08-31-0.3M-163.11K
2026-08-14-0.2M-157.93K
2026-07-31-0.3M-160.24K
2026-07-15-0.3M-173.18K
2026-06-30-0.2M-188.04K
2026-06-15-0.2M-196.21K
2026-05-29-0.3M-207.69K
2026-05-15-0.2M-247.70K
2026-04-30-0.3M-261.43K
2026-04-15-0.4M-262.23K
2026-03-31-0.3M-247.47K
2026-03-13-0.2M-242.48K
2026-02-27-0.4M-211.41K
2026-02-13-0.2M-167.15K
2026-01-30-0.1M-149.25K
2026-01-15-0.2M-134.39K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-29SEC
2026-10-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-21SEC
2026-09-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-30SEC
2026-09-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-21SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-07SEC
2026-09-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-14SEC
2026-09-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-02SEC
2026-09-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-01SEC
2026-08-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-07-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-07-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-01SEC
2026-05-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-05-20SEC
2026-05-183Initial statement of beneficial ownership of securities2026-05-11SEC
2026-05-183Initial statement of beneficial ownership of securities2026-05-11SEC
2026-05-183Initial statement of beneficial ownership of securities2026-05-11SEC
2026-05-064Statement of changes in beneficial ownership of securities2026-04-28SEC
2026-04-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-22SEC
2026-04-23UPLOADUpload SubmissionSEC
2026-04-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-20SEC
2026-04-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-19SEC
2026-04-17CORRESPSEC
2026-04-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-14SEC
2026-04-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-14SEC
2026-04-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-12SEC
2026-04-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-09SEC
2026-04-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-09SEC
2026-04-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-31SEC
2026-04-03UPLOADUpload SubmissionSEC
2026-04-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-01SEC
2026-04-014Statement of changes in beneficial ownership of securities2026-03-29SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0920.00K100
2026-080000
2026-070000
2026-060000
2026-050000
2026-04996.74K200
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC0.16%
BLAIR WILLIAM & CO/IL0.14%
LAZARD ASSET MANAGEMENT LLC0.08%
PORTLAND INVESTMENT COUNSEL INC.0.08%
Hennion & Walsh Asset Management, Inc.0.06%
Private Advisor Group, LLC0.06%
MARSHALL WACE, LLP0.06%
MORGAN STANLEY0.05%
Integrated Wealth Concepts LLC0.05%
Raiffeisen Bank International AG0.03%

Funds

Fund% owned
Voya Global Income & Growth Fund0.29%
Strategic Advisers U.S. Total Stock Fund0.13%
WisdomTree Europe Hedged Equity Fund0.04%
Avantis International Equity ETF0.03%
Goldman Sachs ActiveBeta(R) International Equity ETF0.01%
Touchstone ETF Trust-Touchstone Dynamic International ETF0.01%
Avantis International Large Cap Value ETF0.01%
AST Balanced Asset Allocation Portfolio0.01%
Xtrackers MSCI EAFE Hedged Equity ETF0.01%
AST PGIM Aggressive Multi-Asset Portfolio0.01%

OakChart. TLX. Cached 15 minutes.